|
|
Article: EpiCept Price And Volume Pop On AACR Data, Other Factors?
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Shares of EpiCept Corp. doubled in price early Friday after the Tarrytown, N.C.-based company issued a news release revealing a new mechanism of action for brain cancer drug Azixa (MPC-6827).
Yet a nearly identical news release issued three days earlier by partner Myriad Genetics Inc. elicited little enthusiasm from investors.
Myriad presented data at the American Association for Cancer Research (AACR) annual meeting on Tuesday characterizing Azixa as a vascular disrupting agent (VDA).
The drug had been previously shown to induce apoptosis, but the new data showed VDA activity as demonstrated by tumor blood vessel damage in ...